Oral Immunotherapy to peanut shown to be generally safe in young children
Specific oral tolerance induction (oral immunotherapy) to peanut has received varied opinions, with some studies showing the risk of severe reactions being greater in those undergoing oral immunotherapy than those practising avoidance. But recent studies have supported the overall benefit-risk profile of long-term oral immunotherapy with peanut.
Below are 2 studies showing promising safety data for young children undergoing peanut oral immunotherapy.
1.Data published in the Journal of Allergy and Clinical Immunology: In Practice suggests that oral immunotherapy is safe for preschool-aged children with peanut allergies.
2. A long term follow-up study of peanut immunotherapy, published in Journal of Allergy and Clinical Immunology in May 2021 showed sustained safety and efficacy, as well as further benefits in modulating the immune system, with ongoing daily peanut dosing beyond 1 year.
Post updated 28 May 2021